Oxford Biomedica Solutions
Lori Karpes has extensive experience in the field of drug product sciences and formulation development for gene therapy. Lori is currently serving as the Director of Drug Product Sciences at Oxford Biomedica Solutions since July 2022. Prior to this, Lori worked as the Associate Director of Drug Product Sciences at the same company from March 2022 to July 2022. Before joining Oxford Biomedica Solutions, they held the position of Associate Director of Formulation and Drug Product Process Development Lead at Homology Medicines, Inc. from June 2019 to March 2022. Lori also served as a Senior Scientist and Drug Product Sciences Group Lead at Voyager Therapeutics, Inc. from April 2018 to May 2019. Their earlier experience includes roles at Biogen, where they worked as a Scientist II in Gene Therapy Drug Product Development from May 2016 to April 2018, and as a Scientist II and Scientist I in Protein Formulation and Process Development from October 2011 to May 2016.
Lori Karpes completed their Bachelor's degree in Pharmaceutical Sciences from Purdue University, attending from 2003 to 2007. Lori then pursued further education and obtained their Doctorate degree in Pharmaceutics, also from Purdue University, attending from 2007 to 2011.
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.